12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BAX 855: Phase I data

Top-line data from an open-label Phase I trial in 19 previously-treated patients aged 18 years and older with severe hemophilia A showed that BAX 855 had a 1.5-fold higher half-life compared to Advate octocog alfa. No patients developed inhibitors or...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >